Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.
Siersbæk R, Scabia V, Nagarajan S, Chernukhin I, Papachristou EK, Broome R, Johnston SJ, Joosten SEP, Green AR, Kumar S, Jones J, Omarjee S, Alvarez-Fernandez R, Glont S, Aitken SJ, Kishore K, Cheeseman D, Rakha EA, D'Santos C, Zwart W, Russell A, Brisken C, Carroll JS. Siersbæk R, et al. Among authors: joosten sep. Cancer Cell. 2020 Sep 14;38(3):412-423.e9. doi: 10.1016/j.ccell.2020.06.007. Epub 2020 Jul 16. Cancer Cell. 2020. PMID: 32679107 Free PMC article.
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.
Severson TM, Kim Y, Joosten SEP, Schuurman K, van der Groep P, Moelans CB, Ter Hoeve ND, Manson QF, Martens JW, van Deurzen CHM, Barbe E, Hedenfalk I, Bult P, Smit VTHBM, Linn SC, van Diest PJ, Wessels L, Zwart W. Severson TM, et al. Among authors: joosten sep. Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2. Nat Commun. 2018. PMID: 29396493 Free PMC article.
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S, Alsaleem M, Monteiro CJ, Bhardwaj K, Joosten SEP, Fujii T, Shirabe K, Green AR, Ellis IO, Rakha EA, Mongan NP, Heery DM, Zwart W, Oesterreich S, Johnston SJ. Kurozumi S, et al. Among authors: joosten sep. Breast Cancer Res. 2020 Aug 11;22(1):85. doi: 10.1186/s13058-020-01324-4. Breast Cancer Res. 2020. PMID: 32782013 Free PMC article.
Perturbations in 3D genome organization can promote acquired drug resistance.
Manjón AG, Manzo SG, Prekovic S, Potgeter L, van Schaik T, Liu NQ, Flach K, Peric-Hupkes D, Joosten S, Teunissen H, Friskes A, Ilic M, Hintzen D, Franceschini-Santos VH, Zwart W, de Wit E, van Steensel B, Medema RH. Manjón AG, et al. Cell Rep. 2023 Oct 31;42(10):113124. doi: 10.1016/j.celrep.2023.113124. Epub 2023 Sep 20. Cell Rep. 2023. PMID: 37733591 Free article.
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP, Gregoricchio S, Stelloo S, Yapıcı E, Huang CF, Yavuz K, Donaldson Collier M, Morova T, Altintaş UB, Kim Y, Canisius S, Moelans CB, van Diest PJ, Korkmaz G, Lack NA, Vermeulen M, Linn SC, Zwart W. Joosten SEP, et al. Genome Res. 2024 May 15;34(4):539-555. doi: 10.1101/gr.278680.123. Genome Res. 2024. PMID: 38719469
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.
Joosten SEP, Wellenstein M, Koornstra R, van Rossum A, Sanders J, van der Noort V, Ferrandez MC, Harkes R, Mandjes IAM, Rosing H, Huitema A, Beijnen JH, Wesseling J, van Diest PJ, Horlings HM, Linn SC, Zwart W. Joosten SEP, et al. NPJ Breast Cancer. 2021 Oct 20;7(1):138. doi: 10.1038/s41523-021-00344-3. NPJ Breast Cancer. 2021. PMID: 34671036 Free PMC article.
Double-strand break toxicity is chromatin context independent.
Friskes A, Koob L, Krenning L, Severson TM, Koeleman ES, Vergara X, Schubert M, van den Berg J, Evers B, Manjón AG, Joosten S, Kim Y, Zwart W, Medema RH. Friskes A, et al. Nucleic Acids Res. 2022 Sep 23;50(17):9930-9947. doi: 10.1093/nar/gkac758. Nucleic Acids Res. 2022. PMID: 36107780 Free PMC article.
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, Bhattacharya A, Joosten SEP, Da Silva AM, Padrao N, Wellenstein MD, Kersten K, de Boo M, Roorda M, Henneman L, de Bruijn R, Annunziato S, van der Burg E, Drenth AP, Lutz C, Endres T, van de Ven M, Eilers M, Wessels L, de Visser KE, Zwart W, Fehrmann RSN, van Vugt MATM, Jonkers J. Zimmerli D, et al. Among authors: joosten sep. Nat Commun. 2022 Nov 2;13(1):6579. doi: 10.1038/s41467-022-34000-6. Nat Commun. 2022. PMID: 36323660 Free PMC article.
14 results